Open AccessImatinib-induced extensive hyperpigmentation in a case of chronic myeloid leukemia
Author(s) -
Pradeep Balasubramanian,
Soumya Jagadeesan,
Jacob Thomas
Publication year - 2015
Publication title -
indian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.395
H-Index - 36
eISSN - 1998-3611
pISSN - 0019-5154
DOI - 10.4103/0019-5154.164447
Subject(s) - myeloid leukemia , imatinib , hypopigmentation , hyperpigmentation , medicine , tyrosine kinase inhibitor , tyrosine kinase , nilotinib , imatinib mesylate , cancer research , leukemia , dermatology , cancer , receptor
Imatinib, a tyrosine kinase inhibitor, is well known to cause hypopigmentation because of its inhibitory effect on melanocytes. Herewith we report a case of chronic myeloid leukemia who developed extensive hyperpigmentation following imatinib therapy
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom